<SEC-DOCUMENT>0001193125-23-008959.txt : 20230117
<SEC-HEADER>0001193125-23-008959.hdr.sgml : 20230117
<ACCEPTANCE-DATETIME>20230117082430
ACCESSION NUMBER:		0001193125-23-008959
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230117
FILED AS OF DATE:		20230117
DATE AS OF CHANGE:		20230117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		23530342

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d426692d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of January, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;16, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX announcement titled, &#147;Kazia Raises
A$4.5 Million to Progress R&amp;D Programs.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, into the Company&#146;s registration
statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d426692dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated January&nbsp;16, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 17&nbsp;January 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d426692dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g426692dsp3.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">January&nbsp;16, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA RAISES A$4.5 MILLION TO PROGRESS R&amp;D PROGRAMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, January</B><B></B><B>&nbsp;16, 2023 &#150; </B>Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology
company, is pleased to announce a placement of KZA shares, to institutional and sophisticated investors in Australia, at a price of A$0.11 per share. The placement will raise A$4.5&nbsp;million (exclusive of costs). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Placement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Placement to professional and
sophisticated investors consists of an: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A$2,792,572 unconditional institutional placement of 25,387,018 New Shares, representing approximately 16% of the
total shares of Kazia on issue prior to the issue of the New Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A$1,707,428 institutional placement of 15,522,075 New Shares, conditional on Kazia shareholder approval for the
purposes of ASX Listing Rule 7.1. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The price of both the Unconditional Placement and the Conditional Placement will be A$0.11 which
represents a 13% premium to the <FONT STYLE="white-space:nowrap">15-day</FONT> volume-weighted average price (VWAP) on the Australian Securities Exchange (<B>ASX</B>) up to and including 11&nbsp;January 2023 of A$0.097. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Shares to be issued under the Unconditional Placement will be issued without shareholder approval under the Company&#146;s existing placement capacity
under ASX Listing Rules 7.1. Settlement and issuance of shares is expected to occur on or around January&nbsp;16, 2023, with quotation expected on January&nbsp;17, 2023 in Australia. The New Shares will rank equally with the Company&#146;s existing
shares on issue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An Extraordinary General Meeting (<B>EGM</B>) is expected to be held on 24&nbsp;February 2023 to seek approval for the issuance of New
Shares under the Conditional Placement. Kazia will provide eligible shareholders with a notice of meeting and explanatory materials over the coming days. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Placement was not underwritten. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Funding will be used to
drive Kazia&#146;s clinical program toward several critical inflection points, including the final data read out on the paxalisib GBM AGILE study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ENDS] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This announcement may include forward-looking statements</I>, <I>which can generally be identified as
such by the use of words such as </I><I>&#147;</I><I>may,</I><I>&#148;</I><I> </I><I>&#147;</I><I>will,</I><I>&#148;</I><I> </I><I>&#147;</I><I>estimate,</I><I>&#148;</I><I> </I><I>&#147;</I><I>future,</I><I>&#148;</I><I>
</I><I>&#147;</I><I>forward,</I><I>&#148;</I><I> expect,</I><I>&#148;</I><I> </I><I>&#147;</I><I>anticipate,</I><I>&#148;</I><I> or other similar words. Any statement describing </I><I>Kazia&#146;s</I><I> future plans, strategies, intentions,
expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding the placement of shares and the company</I><I>&#146;</I><I>s
plans with respect to the proceeds from the placement</I><I>. These forward-looking statements are based on </I><I>Kazia</I><I>&#146;</I><I>s</I><I> expectations and beliefs concerning future events. Forward-looking statements are necessarily
subject to risks, uncertainties and other factors, many of which are outside the control of </I><I>Kazia</I><I>, which could cause actual results to differ materially from such statements. </I><I>These and other risks and uncertainties are described
more fully in </I><I>Kazia</I><I>&#146;</I><I>s</I><I> Annual Report, filed on Form <FONT STYLE="white-space:nowrap">20-F</FONT> with the Securities and Exchange Commission (SEC), and in other filings with the SEC. </I><I>Kazia</I><I> makes no
undertaking to subsequently update or revise the forward-looking statements made in this announcement, to reflect the circumstances or events after the date of this announcement. </I><I>You should not place undue reliance on these forward-looking
statements, whi</I><I>ch apply only as of the date of this announcement.</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This release does not constitute an offer to sell, or a solicitation of
an offer to buy, securities in the United States or to U.S. persons (as defined in Rule&nbsp;902 under the Securities Act of 1933, as amended (the Securities Act)), or for the account or benefit of U.S. persons. The securities referred to in this
announcement have not been registered under the Securities Act, or under the securities laws of any state or other jurisdiction of the United States. Accordingly, such securities may not be offered or sold, directly or indirectly, in the United
States or to any U.S. persons or to any person acting for the account or benefit of a U.S. person, except in transactions (i)&nbsp;registered under the Securities Act or (ii)&nbsp;exempt from, or not subject to, the registration requirements of the
Securities Act and any other applicable securities laws of any state or other jurisdiction of the United States. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g426692dsp3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g426692dsp3.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * %1'D<)
M&I=SP%49)H2OL)M)78Z6"6"3RYHGC?\ NNI!IM-:,(R4E=,=-:W%N%,\$D0;
M[N]2,_G0XM;H49QE\+N14B@H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#AAZTU)/03BT8M42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &WX:TNUU.[E6Y)*QKD(#C=6U&"F]3CQ=:5**<2VWV/PUXG! 9X#'TZF//
M_P"K\C5^[2J&:Y\50\_S(]9UVUN]6LKB"(O';-DEA@OR#C]*52JI2370=##S
MA3E&3W)O$.OV6I6$=O;ABQ<,69<;:=6K&<;(G"X:=*;E(FU7PYI]GHC7$3L)
M8U!#ELA_PJJE&,871%'%5)U>5['(UR'J!0 4 % !0 4 % !0 >PH * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M61X)72<X4 >E?!_P]]NUF;69TS#9#;'D<&0C^@_F*RJ2LK&M-:W,+XC>'O\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /,TK6Z0%R8D8NJ=@2 "?\
MQT?E0 R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3G^R!IWRJ^>?E7H!T[#%:*<4K&3A)NYYE+$T,SQ/PR,5/U%;&19TK_D,6/\
MUW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<YWOPH\/?VKXF_M"
M9,VVG@2<C@R'[H_#D_@*RJ.RL:4U=W/6O$,OA34!_9VNWMD?)8.89;G85.."
M0".Q_6L8\RU1L^5Z,LZ,WA^736TK2+BUGM(D*M#%,) JMG@\DX/-#O>[&K;(
M^=_%.AOX=\1WFFMG9&^8F/\ $AY4_E^M=,7=7.:2L[&/5$A0 4 % !0 4 %
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MN*L<[J%]+J6I7-].%$MQ*TKA1@ DY.*I*RL2W=W.PL/BQXBL-/AL]MI.L2;
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M:7,ZF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVMQ4TUC:K/+<0P"0$QK(3EP/H./QH4-+MB=5*7*DV(=/9+!+MYHD#@E$.=S
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *CO&X>-V1AT*G!%"=MA-)JS+FFZG-IM^+M1YC8(8,?O ^]7";A*
MYE5HJK#D+6I>()]0O;>X6-8OLYW(N<\Y!Y_(54ZKDT^QG2PT:<7&][DFK>))
MM4LUMC L2Y!8@YSC^5.I6<U8FAA(T9<U[F,9'9 A=B@Z*3P*QN==DG<;0,*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
